A. Hejjaoui

发表

Heterogeneity of atopy. I. Clinical and immunologic characteristics of patients allergic to cypress pollen

J. Bousquet, F. Michel, R. Ferrando, 1993, Allergy.

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment.

J. Bousquet, B. Guérin, F. Michel, 1985, The Journal of allergy and clinical immunology.

Skin test reactivity in patients suffering from lung and breast cancer.

J. Bousquet, J. Pujol, P. Godard, 1991, The Journal of allergy and clinical immunology.

Specific immunotherapy in asthma.

J. Bousquet, F. Michel, A. Hejjaoui, 1990, The Journal of allergy and clinical immunology.

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy.

J. Bousquet, F. Michel, A. Hejjaoui, 1988, The Journal of allergy and clinical immunology.

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract.

J. Bousquet, P. Chanez, L. Paradis, 1996 .

Systemic reactions occurring during immunotherapy with standardized pollen extracts.

J. Bousquet, F. Michel, R. Ferrando, 1992, The Journal of allergy and clinical immunology.

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid.

J. Bousquet, F. Michel, A. Hejjaoui, 1990, The Journal of allergy and clinical immunology.

Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy.

J. Bousquet, B. Guérin, F. Michel, 1988, The Journal of allergy and clinical immunology.

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma.

J. Bousquet, F. Michel, A. Hejjaoui, 1989, The Journal of allergy and clinical immunology.

Clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. I. Clinical and immunologic characteristics.

J. Bousquet, W. Becker, F. Michel, 1991, The Journal of allergy and clinical immunology.

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule.

J. Bousquet, F. Michel, A. Hejjaoui, 1990, The Journal of allergy and clinical immunology.

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract.

J. Bousquet, B. Guérin, F. Michel, 1987, The Journal of allergy and clinical immunology.

Allergoids for Hyposensitization

J. Bousquet, F. Michel, A. Hejjaoui, 1991 .

Double-blind, placebo-controlled immunotherapy with a high-molecular-weight, formalinized allergoid in grass pollen allergy.

J. Bousquet, F. Michel, A. Hejjaoui, 1987, International archives of allergy and applied immunology.

Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract.

J. Bousquet, F. Michel, A. Hejjaoui, 1990, The Journal of allergy and clinical immunology.

Is diet partly responsible for differences in COVID-19 death rates between and within countries?

Ana C. Coelho, Todor A Popov, I. Pavord, 2020, Clinical and Translational Allergy.

Non‐specific histamine release activity of busereline, LH‐releasing hormone

J. Bousquet, F. Michel, A. Hejjaoui, 1988, Allergy.

Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies

Ana C. Coelho, Todor A Popov, I. Pavord, 2020, Clinical and Translational Allergy.

Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries?

Ana C. Coelho, Todor A Popov, I. Pavord, 2020, Clinical and Translational Allergy.

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation.

J. Bousquet, P. Chanez, L. Paradis, 1996, Allergy.

Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts.

J. Bousquet, W. Becker, F. Michel, 1991, The Journal of allergy and clinical immunology.

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma.

J. Bousquet, F. Michel, A. Hejjaoui, 1989, The Journal of allergy and clinical immunology.